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Oligonucleotide therapeutics hold promise for the treatment of
muscle- and heart-related diseases. However, oligonucleotide
delivery across the continuous endothelium of muscle tissue
is challenging. Here, we demonstrate that docosanoic acid
(DCA) conjugation of small interfering RNAs (siRNAs) en-
ables efficient (~5% of injected dose), sustainable (>1 month),
and non-toxic (no cytokine induction at 100 mg/kg) gene
silencing in both skeletal and cardiac muscles after systemic in-
jection. When designed to target myostatin (muscle growth
regulation gene), siRNAs induced ~55% silencing in various
muscle tissues and 80% silencing in heart, translating into a
~50% increase inmuscle volumewithin 1 week. Our study iden-
tifies compounds for RNAi-based modulation of gene expres-
sion in skeletal and cardiac muscles, paving the way for both
functional genomics studies and therapeutic gene modulation
in muscle and heart.
INTRODUCTION
Therapeutic oligonucleotides have the potential to revolutionize
medicine because of their potency, duration of effect, and ability to
target previously “undruggable” disease genes.1–8 The clinical success
of oligonucleotides is dependent on their efficient delivery to disease
tissues, which is achieved through full chemical stabilization and
conjugation.4,9–19 The trivalent N-acetylgalactosamine (GalNAc)
conjugate, which binds hepatocyte-specific receptors, has dominated
the development of oligonucleotide therapeutics to treat liver dis-
eases, recently demonstrated by the US Food and Drug Administra-
tion (FDA) approval of givosiran.20–24 A single subcutaneous admin-
istration of GalNAc-conjugated small interfering RNAs (siRNAs) can
induce a clinical benefit that lasts up to 6–12 months in humans.8,25
The success of the GalNAc conjugate platform demonstrates that
functional tissue delivery of therapeutic oligonucleotides is the foun-
dation for any clinical exploration.
Oligonucleotide therapeutics holds promise for the treatment of mus-
cle-related diseases.26,27 When injected locally, oligonucleotides can
achieve significant target gene reduction in a small portion of muscle
tissue,28–30 but its limited distribution minimizes potential therapeu-
tic use. When injected systemically, oligonucleotides (and the major-
ity of other drugs) naturally accumulate in liver, which is a primary
filtering tissue with high blood flow volumes and discontinued fenes-
trated epithelia.31 Thus, systemic delivery of oligonucleotides to extra-
hepatic tissues, like muscles, remains a challenge.
Lipid conjugation, such as cholesterol and fatty acids, significantly im-
proves the systemic delivery of oligonucleotides to tissues beyond
liver9,32–36 and supports productive silencing in these extrahepatic tis-
sues.32,33,37,38 However, only limited success in delivering oligonucleo-
tides tomuscle after systemic administration has been reported.37–39 In
the context of siRNAs, only cholesterol conjugation has been evaluated.
Although cholesterol-conjugated siRNAs do deliver to muscles after
intravenous injection,38 a high dose (50 mg/kg) is required to achieve
sustainable gene silencing. Cholesterol conjugates are highly toxic at
high concentrations, limiting their potential for clinical translation.39
Fatty acids are involved in the contractile work of skeletal and cardiac
cells and are efficiently transported across the muscular endothelium
barrier to reach muscle cells,40 making them potentially viable candi-
dates for conjugate-mediated oligonucleotide delivery to muscle.
Indeed, efficient distribution of antisense oligonucleotides (ASOs)
to muscle has already been achieved by conjugating ASOs with fatty
acids.37 Palmitic acid, in particular, allowed for robust silencing in
muscles after systemic injection.39,41 For siRNAs, we previously eval-
uated the impact of fatty acid conjugation on distribution and
silencing activity in a variety of tissues, including muscles. Several
conjugates (e.g., cholesterol, myristic acid [Myr], docosanoic acid
[DCA], eicosapentaenoic acid [EPA], and docosahexanoic acid
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[DHA]) enabled wide distribution profiles,32,33 with DCA variants
showing enhanced cardiac and skeletal muscle delivery after systemic
administration in mice. We further optimized the chemical structure
and linker chemistry of DCA-siRNA to enhance productive silencing
in extrahepatic tissues.42
Here, we evaluated the potential of the optimized DCA-conjugated
siRNA scaffold to silence a therapeutically relevant gene, myostatin,
in muscle and heart. DCA-siRNAs demonstrated productive
(~55%–80%) silencing, which lasts longer than 1 month, translating
into a ~50% increase in muscle volume. Furthermore, an exaggerated
pharmacology study showed a lack of significant cytokine induction
at a high dose (100 mg/kg), demonstrating the therapeutic potential
of DCA-conjugated siRNAs.
RESULTS
Previous identification of an optimized conjugate structure and
siRNA architecture for efficient delivery of siRNAs to muscle
In our previous reports, we synthesized a panel of siRNAs conjugated
with saturated and unsaturated fatty acids of varying carbon chain
length and unsaturation, i.e., Myr (14:0), DCA (22:0), EPA (20:5
n-3), and DHA (22:6 n-3), and evaluated the impact on relative tissue
distribution in mice. Each lipid conjugate was attached to the 30 end of
the siRNA sense strand, which tolerates a range of covalent modifica-
tions .7,39,40 siRNAswere fully chemicallymodified for maximal stabil-
ity and minimal innate immune activation.11–14,17–19,43 Figure S1
shows the cumulative data from these previous reports32,33 in muscle,
heart, and major clearance tissues (liver, kidney).
Approximately 85% of unconjugated siRNAs (control) were cleared
from the body (Figure S1B), with retained compounds accumulating
primarily in kidneys. Fatty acid conjugation enhanced overall com-
pound retention in a structure-dependent manner: 40%–45% of un-
saturated fatty acid siRNAs (EPA and DHA) were retained, whereas
quantitative (~100%) retention was observed with cholesterol (con-
trol) and saturated fatty acid siRNAs (Myr and DCA) (Figure S1B).
The structure of the conjugate also significantly affected tissue distri-
bution (Figures S1C and S2). Cholesterol and a long, saturated chain
(DCA) conjugation led to higher siRNA accumulation in liver (33 and
28 pmol/mg, respectively) than in kidneys (5 and 13 pmol/mg,
respectively). By contrast, siRNAs conjugated with a short, saturated
chain (Myr) or unsaturated chains (EPA and DHA) showed higher
accumulation in kidneys (76, 32, and 34 pmol/mg, respectively)
than in liver (15, 4, and 8 pmol/mg, respectively). Although the
majority of injected siRNAs accumulate in liver and kidneys, a small
fraction of compounds was retained in muscle tissues (up to 4.3% of
injected dose in skeletal muscles and 0.4% in heart) (Figure S1D).
DCA siRNAs distributed to muscle tissues significantly more than
other siRNAs, e.g., 3-fold and 2.5-fold higher accumulation in skeletal
muscle and heart, respectively, compared with cholesterol-siRNAs
(Figure S1C). The difference in accumulation was specific to DCA,
because changing both length (Myr) and degree of saturation (EPA
and DHA) had a negative impact on siRNA accumulation in muscle.
The increase in accumulation translated into functional gene
silencing (of huntingtin mRNA) by DCA-conjugated siRNA in both
skeletal and cardiac muscles (up to 44% silencing; Figure S1E).32
Our previous reports demonstrate that conjugate chemical
structure, which defines serum protein binding and clearance ki-
netics,33,34,37,41,44–46 drives tissue distribution, and that DCA conjuga-
tion may be optimal for siRNA delivery to muscle.
In all experiments reported in Figure S1 and other publications,32,33
lipid conjugates are directly attached to siRNAs using a phospho-
diester carbon linker (PO-C7 linker) (Figure S1A). In our most recent
report,42 we evaluated the impact of linker chemistry on DCA-siRNA
efficacy and found that using a cleavable linker, d(TT) PO-C7 (Fig-
ure S3A), significantly improves huntingtinmRNA silencing in quad-
riceps (by 10%, p < 0.05) and heart (by 19%, p < 0.001) without
altering tissue accumulation (Figures S3B and S3C). This is likely
because the phosphodiester d(TT) linker has limited in vivo stability,
sufficient to support initial tissue distribution, but gets quickly
degraded upon cellular uptake to allow siRNA release from the con-
jugate.47 Collectively, our previous reports identify an optimal conju-
gated siRNA platform for improving delivery to muscle. In the cur-
rent study, we set out to apply our optimal siRNA architecture to
silence a therapeutically relevant gene in muscle.
Experimental design to evaluate dosing and efficacy of d(TT)
PO-C7-linked DCA-conjugated siRNAs targeting a
therapeutically relevant gene,myostatin, in cardiac and skeletal
muscles of mice
Themuscle growth factor,myostatin (Mstn), is emerging as a therapeu-
tic target of interest for the prevention of muscle wasting.48 Mstn (also
knownasGrowthandDifferentiationFactor 8 [GDF-8]) negatively reg-
ulates muscle mass and is primarily expressed in skeletal muscles, with
low mRNA levels also reported in cardiac tissues.49 Mstn inhibition is
associated with increased muscle mass.50,51 We designed d(TT) PO-
C7-linkedDCA-conjugated siRNAs to silenceMstnusing sequences ex-
tracted from Khan et al.38 To better understand the impact of dose on
compound accumulation and efficacy in heart andmuscles, we injected
mice (n = 6 per group) subcutaneously (s.c.) with a range of DCA-
siRNA doses: a single dose at 20 mg/kg (“20”), two doses of 20 mg/kg
given 10 h apart (“2  20”), or six doses administrated over 3 days
(morningandnight, ~10–14hapart, “6 20”). PBS and anon-targeting
siRNA (Ntc, compoundof identical chemical configuration, but not tar-
geting Mstn mRNA) were used as controls for expression and muscle
phenotype analysis. We intentionally dosed within short periods of
time to explore whether saturation of the primary clearance tissues
(liver/kidney) may allow for better siRNA delivery to muscles. At
1week and 1month post-injection, wemeasured siRNA tissue accumu-
lation andMstn expression (mRNA and protein). To evaluate the effect
of DCA-siRNA-mediated Mstn inhibition on muscle growth, we also
measured muscle size/weight at 1 week and 1 month post-injection.
siRNA dosing regimen must be optimized separately for muscle
and heart delivery
To evaluate siRNA tissue accumulation, which is predictive of dura-
tion of effect,11,13,52 we quantified antisense strands in liver, heart,
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gastrocnemius muscle, and quadriceps at either 1 week or 1 month
post-injection using the peptide nucleic acid (PNA) hybridization
assay (see Materials and methods) (Figure 1A). siRNA accumulation
in tissues is independent of the target, but it is mainly driven by the
chemical composition and conjugate.32,34,42 Therefore, the evaluation
of the distribution of a non-targeting DCA-conjugated siRNA was
not necessary as control because it has a similar distribution of target-
ing DCA-conjugated siRNA, where the conjugate DCA drives distri-
bution and level of accumulation. To estimate the fraction of the
injected dose retained in different tissues (Figure 1B), we based the
calculations on either the actual weight of the organs when experi-
mentally measurable (for liver and heart) or on published mouse
organ weights (for total muscle weight) corresponding to the same
mouse strain, sex, and age.53–55 Consistent with our previous report,
DCA-conjugated siRNAs accumulated preferentially in liver (Fig-
ure 1; Figure S4), but a significant fraction of the injected dose accu-
mulated in cardiac (up to 0.3%) and skeletal (up to 2.5%) muscles
(Figure 1B). The compounds distributed to the same extent in various
skeletal muscle types (gastrocnemius and quadriceps), demonstrating
that systemic administration of the compounds enabled uniform
distribution throughout all muscle tissues, which is important for
eventual therapeutic translation.
Changing the dosing regimen had a profoundly different impact on
siRNA accumulation in the tissues tested. At 1 week post-injection,
two doses within 10 h led to a ~2-fold increase in compound accumu-
lation in liver compared with a single dose (20 versus 2  20 mg/kg)
(Figure 1A), suggesting that the liver was not saturated after thefirst in-
jection. However, four additional doses in the next 48 h (6 20mg/kg)
led to only a 1.7-fold increase in accumulation (2  20 versus
6  20 mg/kg), and a large fraction of the compounds got cleared
(~65% of the injected dose; Figure 1B). Thus, two injections at
20 mg/kg within 10 h were sufficient to temporarily saturate the liver.
In skeletal muscles, the opposite trend was observed. No significant
change in accumulation was detected after one versus two injections
(~0.4 versus 0.39 pmol/mg; Figure 1B), suggesting that, at ~10 h, mus-
cle tissues were still saturated with siRNAs from the first dose (Fig-
ure 1A). However, additional doses within the next 48 h enabled a
~2.5-fold (0.95 pmol/mg) increase in accumulation. These results
indicate that doses need to be at least 1 day apart to enable additional
siRNA accumulation in skeletal muscles. Interestingly, in heart,
changing the dosing regimen had no significant impact on compound
accumulation. One, two, or six injections within 3 days led to a similar
level of compound accumulation (~1.4, ~1.6, and ~1.7 pmol/mg,
respectively; ~8% increase) (Figure 1A), indicating that a single
dose was sufficient to saturate heart tissue. It is likely that a longer
gap between the doses (>3 days) would be necessary to enhance
siRNA accumulation in the heart. Collectively, these results demon-
strate that dosing regimen and dosing time period need to be defined
and optimized separately for different tissues to maximize compound
tissue accumulation.
At 1 month post-injection, a decrease in compound accumulation
was observed in all tissues (~4-fold decrease compared with 1-week
accumulation) at the 2 20 mg/kg dose (Figure 1A). However, a sig-
nificant level of siRNAs was still detectable in heart and skeletal
muscles (0.36 and 0.12 pmol/mg, respectively), showing that DCA-
conjugated fully chemically stabilized siRNAs achieve sustained mus-
cle and heart accumulation.
Figure 1. DCA conjugate supports significant accumulation in muscle tissues after s.c. injection at 1 week and 1 month post-injection
(A) Bar graph showing siRNA quantification after 1 week (20, 2 20, and 6 20mg/kg) and 1month (2 20mg/kg 1month) post-injection in liver, heart, gastrocnemius, and
quadriceps, measured by PNA hybridization assay (average of n = 6 ± SD). Data analysis: t test (****p < 0.0001, ***p < 0.001, **p < 0.01). (B) Table summarizing percent of
injected dose retained in liver, heart, and muscles (average of 6 mice ± SD).
www.moleculartherapy.org
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d(TT) PO-C7-linked DCA-siRNAs induce sustained silencing of
Mstn mRNA in muscles and reduced Mstn protein levels
To evaluate whether the observed levels of siRNA accumulation
correlated with observed silencing, we measured Mstn expression
in heart, gastrocnemius, and quadriceps muscle at either 1 week
or 1 month post-injection (Figures 2 and 3). Non-targeting controls
(Ntc) (a compound of identical chemical configuration and DCA
conjugated) showed no significant reduction in target gene expres-
sion, indicating that the observed silencing is due to sequence-spe-
cific effects, not the general siRNA chemical scaffold. For all doses
tested, significant silencing of Mstn mRNA was achieved (Fig-
ure 2A). In skeletal muscles (gastrocnemius and quadriceps), a
dose-dependent reduction in Mstn mRNA levels was observed:
one injection induced 30% silencing (p < 0.01), two injections
induced 40% silencing (p < 0.001), and six injections induced
51%–56% silencing (p < 0.0001). Although there was a positive
trend between higher accumulation and higher silencing efficacy,
the observed correlation did not reach statistical significance.
For example, injecting six doses (6  20 mg/kg) versus two doses
(2  20 mg/kg) of siRNA resulted in a ~2.5-fold increase
(p < 0.0002) in accumulation (Figure 1) but no significant difference
in observed silencing (51%–56% versus 40%–41%; Figure 2A). Thus,
although higher accumulation translates toward longer duration of
effect, a large number of repeated doses was not necessary, and
two doses were sufficient to induce significant activity in skeletal
muscles. In cardiac tissue, all doses tested led to similar
accumulation (Figure 1; Figure S4) and induced similar silencing
Figure 2. Significant silencing of Mstn mRNA and
MSTN protein in muscles is achieved using DCA-
conjugated siRNAs
(A) Percent of Mstn mRNA silencing in gastrocnemius,
quadriceps, and heart after s.c. injection of DCA-conju-
gated siRNA in mice sacrificed at 1 week post-injection
(n = 6 mice per group; 20, 2  20, and 6  20 mg/kg).
mRNA levels were measured using QuantiGene (Affyme-
trix), normalized to a housekeeping gene, Hprt (hypo-
xanthine-guanine phosphoribosyl transferase), and pre-
sented as percent of Ntc (mean ± SD). (B) Percent of
MSTN protein levels in serum and quadriceps. s.c. injec-
tion of DCA-conjugated siRNA in mice sacrificed at
1 week post-injection (n = 6 mice per group; 20, 2  20,
and 6  20 mg/kg). Protein levels were measured using
GDF-8/MSTN Quantikine ELISA kit (R&D Systems), pre-
sented as percent of PBS. Data analysis: multiple com-
parisons = one-way ANOVA, Dunnett test (****p < 0.0001,
***p < 0.001, **p < 0.01, *p < 0.1). n.s., non-significant.
(73%–79% silencing; p < 0.0001; Figure 2A),
with no significant difference compared with
the single dose.
To evaluate the duration of observed silencing,
which is critical for potential clinical applica-
tions, we evaluated Mstn mRNA expression
in tissues 1 month post-injection (2  20 mg/kg 1 month) (Fig-
ure 3A). Two doses were s.c. administrated because this dose
regimen was sufficient to induce significant silencing at 1 week
post-injection. We observed robust silencing in both skeletal and
cardiac muscle tissues. Most importantly, there was no statistically
significant difference in silencing between 1 week and 1 month
post-injection: 40% versus 38% in gastrocnemius muscle, 41%
versus 43% in quadriceps, and 73% versus 65% in heart (Figure 3A).
These results indicate that s.c. injection of DCA-conjugated siRNAs
induces sustained (at least 1 month) gene silencing. Thus, DCA
conjugation represents a viable platform for reducing gene expres-
sion in muscles and heart.
ReducedMstnmRNA levels correlated with reductions in serum and
muscle Mstn protein. A higher dose (6  20 mg/kg) induced better
protein silencing (44% in serum and 53% in quadriceps; Figure 2B).
Because serum level is an indicator of cumulative myostatin expres-
sion in the body as a whole, a reduction in MSTN in serum is indic-
ative that there is an overall loss of Mstn silencing. Similarly, at
1 month post-injection, significant Mstn protein silencing was still
observed (Figure 3B), confirming the long-term activity of the siRNA
compound.
Silencing Mstn in muscles using DCA-conjugated siRNAs leads
to a significant increase in muscle volume
For all doses tested, we observed a significant increase in size of
skeletal muscles compared with the control groups (Figure 4A).
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The enhancement of thigh size correlated with the administered
dose and the silencing observed in muscle tissues (Figure 2A). At
1 week post-injection, the lower dose (20 mg/kg) led to an increase
in muscle size of 20%, the intermediate dose (2  20 mg/kg) led to
an increase of 30%, and the higher dose (6  20 mg/kg) led to an
increase of 50%. Remarkably, at 1 month post-injection, the increase
in thigh size was still maintained (30% compared with controls)
and was similar to the thigh size measured at 1 week post-injection
with the same dose injected (2  20 mg/kg). The improvement in
muscle volume was also supported by visual observation of the
mice, showing a major increase in leg muscle size (images in
Figure 4A).
The improvement in muscle size translated to an increase in total
body weight by 6%–8% when compared with PBS groups (Figure 4B).
The difference in body weight was observable as early as day 4 after
the last injection, which may correlate with the beginning of Mstn
gene inhibition and fiber muscle improvement. In addition to skeletal
muscle growth, we observed a significant enhancement of heart
weight when mice were treated with DCA compounds (up to 11% in-
crease) (Figure 4C). However, when normalized to body weight, there
was no significant change compared with the PBS group (<0.3%), sug-
gesting a lack of cardiac hypertrophy. Collectively, these results
demonstrate a long duration of effect to induce muscle growth and
validate the potential of DCA-conjugated siRNAs to achieve clinically
relevant outcomes.
Figure 3. Long-term Mstn mRNA and protein
silencing in muscles is achieved using DCA-
conjugated siRNAs
(A) Percent of Mstn mRNA silencing in gastrocnemius,
quadriceps, and heart after s.c. injection of DCA-conju-
gated siRNA in mice sacrificed at 1 week and 1 month
post-injection (n = 6 mice per group; 2  20 mg/kg).
mRNA levels were measured using QuantiGene (Affyme-
trix), normalized to a housekeeping gene, Hprt, and pre-
sented as percent of Ntc (mean ± SD). (B) Percent of
MSTN protein levels in serum and quadriceps. s.c. injec-
tion of DCA-conjugated siRNA in mice sacrificed at
1 week and 1 month post-injection (n = 6 mice per group,
2  20 mg/kg). Protein levels were measured using GDF-
8/MSTN Quantikine ELISA kit (R&D Systems), presented
as percent of PBS. Data analysis: multiple comparisons =
one-way ANOVA, Dunnett test (**p < 0.01).
DCA-conjugated siRNAs do not induce
cytokine elevation
Dose-limiting toxicity of highly chemically
modified oligonucleotides has been observed,
restraining their potential clinical transla-
tion.56 To evaluate the toxicity of DCA-conju-
gated siRNAs and determine whether DCA
can be used safely, we measured cytokine
levels in mice (n = 3 per group) after s.c. injec-
tion of compounds at 50 mg/kg and at a
high dose of 100 mg/kg. As a reference, cholesterol-conjugated
siRNAs were also injected at the same doses. A large panel
(34 in total) of cytokines was evaluated, including interleukins, col-
ony-stimulating factors, chemokines, and interferons (Figure 5;
Figure S5).
As expected, a high dose (100 mg/kg) of cholesterol-conjugated
siRNAs significantly elevated all cytokine levels. Increases of 2- to
3-fold in interleukin, 2- to 7-fold in colony-stimulating factor, 3- to
80-fold in chemokine, and 2- to 3-fold in interferon concentrations
were observed compared with PBS, and the elevation of 33 out of
34 cytokines reached statistical significance (Figure 5). At the lower
dose (50 mg/kg), cholesterol was tolerated and did not generate sig-
nificant increases in cytokine levels, except for the chemokines IP10
(p < 0.001) and MCP-3 (p < 0.001). These results confirmed that
cholesterol conjugation is not a viable therapeutic paradigm for sys-
temic delivery due to its dose-limiting toxicity and limited therapeutic
index. Remarkably, at both doses (50 and 100 mg/kg), DCA-conju-
gated compounds did not induce any statistically significant enhance-
ment in cytokine levels. These results demonstrate that DCA is signif-
icantly safer than cholesterol and may have potential as a therapeutic
for muscle-related diseases.
In addition, even if after a single injection at high doses (100 mg/kg)
DCA-conjugated siRNAs do not induce significant cytokine eleva-
tion, repetitive injections at lower doses (as reported in this study)
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may result in a different toxicity profile. Therefore, cytokine levels
have been evaluated in mice (n = 3) after either a single injection
(20 mg/kg) or multiple injections (2  20 and 6  20 mg/kg) of
DCA-conjugated siRNAs (Figure 6; Figure S6). For all the dose regi-
mens tested, no significant cytokine elevation has been observed,
except for the chemokine MCP-3 (p < 0.001) after six injections of
20 mg/kg. These results confirmed that DCA conjugate did not
induce a significant increase in cytokine levels, demonstrating that
Figure 4. Mstn silencing in muscles leads to a significant increase in muscle growth
(A) Thigh diameter normalized to PBS and representative images ofmouse hindlimbs after injection at various doses. (B) Bodyweight normalized to body weight at day2. (C)
Relative change in heart weight compared with PBS group and heart weight/body weight ratio normalized to the PBS group. s.c. injection of DCA-conjugated siRNA in mice
sacrificed at 1 week and 1 month post-injection (n = 6 mice per group, mean ± SD; 20, 2 20, and 6 20 mg/kg). Data analysis: multiple comparisons = one-way ANOVA,
Dunnett test and two-way ANOVA, Tukey test (****p < 0.0001, ***p < 0.001, **p < 0.01).
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Figure 5. DCA conjugate shows a safe cytokine profile at high doses
Bar graph showing cytokine levels relative to PBS. 24 h after s.c. injections of DCA- and cholesterol-conjugated siRNAs at 50 and 100 mg/kg (n = 3 mice per group,
mean ± SD). Data analysis: multiple comparisons = one-way ANOVA, Dunnett test (****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.1).
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multiple dosing of DCA compounds can be performed without
concern of toxicity.
DISCUSSION
Although transformative for liver delivery, GalNAc conjugation does
not allow significant oligonucleotide accumulation in tissues other
than liver and kidneys.19,57 Inefficient systemic delivery of oligonucle-
otides to skeletal and cardiac muscle remains a major roadblock in the
development of sustainable drugs for muscle disorders.26,58,59 Several
ASOs are currently in pre-clinical and clinical development for the
treatment of multiple muscle diseases;60,61 however, their inefficient
delivery to muscle requires the use of higher doses than that used
for GalNAc compounds in liver,62 resulting in dose-limiting toxic-
ities.56 We and others have shown that fatty acid conjugation to oli-
gonucleotides supports broad tissue distribution and induces
silencing in several extrahepatic tissues;9,32–34,36–39,46 thus, it repre-
sents a viable approach for improving systemic delivery of com-
pounds to muscles. In our previous reports,32,33 we demonstrate
that DCA is optimal for efficient delivery to, and sustainable
gene silencing in, skeletal and cardiac muscles. Here, we designed
chemically optimized DCA-conjugated siRNAs to silence Mstn and
optimized a dosing regimen for muscle delivery. Mstn silencing by
DCA-siRNAs led to muscle growth without causing toxicity, vali-
dating the therapeutic potential of this compound. Our findings pro-
vide a foundation for developing efficient therapeutic siRNA for the
treatment of muscle disorders.
Previous reports clearly demonstrate the impact of conjugate struc-
ture on the extrahepatic tissue distribution and efficacy of siRNAs.
The higher accumulation of DCA-siRNA in muscle compared with
unconjugated (~7 fold) and other conjugated siRNAs (e.g., ~2.5-
fold higher than cholesterol-siRNAs) (Figure S1)32,33 can be ex-
plained by differences in binding affinity to serum lipoproteins, which
dictate siRNA plasma circulation and tissue exposure.33,34,37,41,45,46,63
Long, saturated fatty acids like DCA bind low-density lipoprotein
(LDL), whereas unsaturated and short-chain saturated fatty acids pri-
marily bind high-density lipoprotein (HDL).34,37,46 In muscle, the
higher siRNA accumulation correlates to productive gene silencing,
Figure 6. DCA conjugate shows a safe cytokine
profile after multiple injections
Bar graph showing cytokine levels relative to PBS. 1 week
after s.c. injections of DCA-conjugated siRNAs at 20,
2 20, and 6 20 mg/kg (n = 3 mice per group, mean ±
SD). Data analysis: multiple comparisons = one-way
ANOVA, Dunnett test (****p < 0.0001, ***p < 0.001,
**p < 0.01, *p < 0.1).
but the use of a cleavable linker (d(TT)) can
further increase siRNA activity in muscle and
heart (and other tissues) without changing
accumulation.47 This is likely because cleavable
linkers enhance endosomal escape of conju-
gated oligonucleotides in cells.42,64,65 Fine-tun-
ing the conjugate and linker chemistries of siRNA is crucial to opti-
mizing functional delivery in extrahepatic tissues.
In the context of ASOs, the same optimization principles may not
apply. Prakash et al.37 found that high binding affinity to plasma al-
bumin (not HDL/LDL) correlated to high ASO activity in muscles.
Moreover, the highest protein binding affinity was observed with fatty
acid chain lengths from 16 to 18 carbons, with degree of unsaturation
having no influence. These differences in protein binding and fatty
acid structure that impact efficacy may be because of the difference
in phosphorothioate (PS) content, which has been shown to impact
protein binding, in ASOs compared with siRNAs. ASOs are single-
stranded fully phosphorothioated compounds, making these modifi-
cations a significant contributor to protein binding.15,66,67 siRNAs, in
contrast, are only partially phosphorothioated; thus, the relative
contribution of PS modifications to protein binding (~9–10 contin-
uous modifications enables protein association68) and tissue distribu-
tion42 may be smaller than that of the conjugate structure. Interest-
ingly, Prakash et al.37 also did not observe changes in ASO activity
with a cleavable d(TCA) linker, indicating that chemical structure dif-
ferences between two classes of oligonucleotide (ASO versus siRNA)
have a profound impact on PK/PD properties, and optimization prin-
ciples may be different between ASOs and siRNAs.
In this study, we build on our previous siRNA findings by demon-
strating that observed gene silencing in skeletal and cardiac muscles
after systemic injection of DCA-conjugated siRNAs is not target spe-
cific. DCA-conjugated siRNAs induced robust and prolonged Mstn
mRNA and protein silencing in muscles, leading to increased muscle
growth. The observed silencing and change in phenotype were still
maintained even 1 month after injection, demonstrating sustained ef-
ficacy. The accumulation in cardiac muscle was superior (~1.5 pmol/
mg) relative to skeletal muscles (~0.4 pmol/mg), and 25% of siRNAs
present at 1 week post-injection remained at 1 month (~0.38 pmol/
mg), sufficient to maintain ~65% silencing. Why does heart accumu-
late more siRNA than skeletal muscles? Although both skeletal and
cardiac muscles have generally similar endothelial structure, small
changes in endothelial cell number and arrangement (which can be
Molecular Therapy
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affected by a disease state) might significantly impact accumulation
and efficacy. Moreover, blood volumes and overall drug exposure
are naturally higher in heart.
An interesting phenomenon observed in this current study is siRNA
delivery saturation: above certain levels of siRNA accumulation in tis-
sues and within certain periods of time, additional dosing of siRNA
does not increase compound accumulation or efficacy in tissues.
This saturation phenomenon, which has not previously been re-
ported, presents differently in different tissues. In liver, an extra
dose administrated within 12 h resulted in a 2-fold increase in accu-
mulation, indicating that the initial dose of oligonucleotides
(20 mg/kg) either did not saturate the liver or liver uptake mecha-
nisms recovered over a 12-h period. Additional doses delivered within
the next 48 h did not proportionally increase accumulation, suggest-
ing two doses within 12 h might be optimal to deliver siRNAs. By
contrast, only a single dose was needed to fully saturate the heart. It
is clear that the maximum amount of oligonucleotide uptake is tissue
specific: only ~1.8 pmol/mg was needed to reach saturation in heart,
whereas ~27 pmol/mg did not fully saturate liver. Liver is a primary
clearance tissue that relies on multiple mechanisms of internalization
for blood/tissue exchange. These mechanisms of uptake in liver may
not translate to equivalent levels of productive RNA-induced
silencing complex (RISC) loading and silencing. In the heart, the
extent of blood exchange is significantly less, but the uptake mecha-
nisms may provide better functional access. Indeed, we and others
have previously reported the disproportionally higher level of com-
pound accumulation necessary to achieve productive silencing in pri-
mary clearance tissues compared with other tissues, such as muscle.32
In skeletal muscles, we observed a third saturation scenario. An extra
dose of siRNA within 12 h had no impact on accumulation, suggest-
ing the tissue was still saturated 12 h after injection. However, addi-
tional doses within the next 48 h resulted in a ~2.5-fold increase in
accumulation. Collectively, these results advance our current knowl-
edge of siRNA development by demonstrating that the dosing
regimen of siRNAs also needs to be optimized to support optimal
duration of effect in a specific tissue of interest.
When targetingMstn, DCA-siRNA achieved silencing levels that sup-
ported profound changes in phenotype. The degree of silencing was
proportional to the injected dose and to muscle volume growth. In
addition, both the degree of muscle silencing and the degree of muscle
increase were consistent over a period from 1 week to 1 month. These
data demonstrate that specific dosing can be used to achieve and
maintain different degrees of target modulation.
Accumulation is predictive of duration of effect.11,13,52 We observed
~0.12 pmol/mg siRNAs in skeletal muscles after 1 month post-injec-
tion, which was still sufficient to maintain ~40% silencing. In heart
tissue, we observed higher accumulation: at 1 month, there was still
~0.4 pmol/mg siRNAs in the tissue, which is likely to support
silencing for more than 2 months in rodents with a single injection.
Further studies will need to be performed to estimate the limits of
the duration of effect. At this point, it is estimated that monthly
dosing in mice would be sufficient to maintain activity. With
siRNAs and ASOs, the potency and duration of effect seem to increase
with translation from rodents to non-human primates to humans.
For example, with inclisiran, a 3-week duration of effect in rodents
translated into more than 6 months of efficacy in humans.8,25 Thus,
it is possible that the sustained modulation of Mstn expression in
muscles and heart might show much longer duration of effect in hu-
mans, which has important implications for therapeutic applications.
In tissues such as muscles, tissue damage can be caused by the disease,
leading to an increase of oligonucleotide accumulation in muscular
tissues. Therefore, we expect that the DCA performance to deliver
siRNA to muscles observed here in healthy mice will be better in dis-
ease models. With that said, it is always unknown how the disease
state might impact siRNA accumulation, and thus the exact distribu-
tion and efficacy will need to be confirmed in disease models.
In addition, distribution and efficacy of hydrophobic-conjugated
siRNAs (e.g., DCA-conjugated siRNAs) rely on serum protein
composition, which may be heavily affected by the animal diet. In
the future, it would be interesting to systematically explore how
high-fat diet (increase in LDL content) versus starvation will impact
distribution of this class of oligonucleotides, which, theoretically, can
be substantial.
Although hydrophobic conjugation supports wide extrahepatic
delivery9,32 and, in the context of structurally optimized siRNAs,
can induce functional relevant silencing,42 toxicity concerns have
limited their therapeutic translation. Indeed, cholesterol-conjugated
siRNAs, the only conjugate reported to deliver siRNAs to muscles
after systemic administration,38 induce a substantial cytokine storm
(up to 80-fold increases for certain markers) at high doses
(~100 mg/kg). By contrast, DCA-siRNAs did not induce cytokines
or any other observable adverse events at the same high dose
(100 mg/kg), indicating superior safety. However, like other lipid-
conjugated siRNAs, DCA-siRNAs predominantly accumulate in
clearance tissues (~77% of the injected dose cumulatively). Thus, it
is essential that DCA-mediated modulation of potential therapeutic
targets in clearance tissues is not expected to cause any detrimental
effects.36 Alternatively, the technology may be optimal in contexts
where the target genes are selectively expressed in muscle and heart,
like Mstn48 or DUX4.69
As of the publication of this article, only ASO-mediated splicing
modulations have been approved by the FDA to treat muscle-related
diseases, such as Duchenne muscular dystrophy (DMA) (eteplirsen
and golodirsen) and spinal muscular atrophy (SMA) (nusinersen).70
Promising data have been reported, showing an increase in dystro-
phin expression.26,71 Although encouraging clinical results have
been observed, the limited ASO delivery to muscles requires the use
of high doses, which can lead to renal toxicity,71 and thus limiting
the use of ASO for the treatment of muscle-related diseases.56 The
DCA platform described in this manuscript allows efficient
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oligonucleotide delivery in muscles after systemic administration,
leading to significant target reduction in both cardiac and skeletal
muscles (up to 80%) and enabling a change in phenotype without
causing any toxicity even at high doses. Therefore, DCA conjugation
provides a safe, sustainable, and robust alternative to treat muscle dis-
orders. In summary, findings from our study demonstrate that DCA
conjugated to structurally optimized siRNA scaffolds can support
efficient, sustained, and safe delivery to muscle and heart after sys-
temic administration. These findings establish a path toward using
RNAi technology for functional genomic studies in muscle and heart
and developing novel therapeutic paradigms for muscle disorders.
MATERIALS AND METHODS
General method for oligonucleotide synthesis
Oligonucleotides were synthesized on a Mermaid 12 synthesizer
following standard protocols. In brief, conjugated sense strands
were synthesized at 10-mmol scales on custom-synthesized lipid-
functionalized controlled pore glass (CPG) supports32,33,72 and were
cleaved and deprotected using 40% aq. methylamine at 45C for 1
h. Antisense strands were synthesized at 10-mmol scales on CPG func-
tionalized with Unylinker (ChemGenes, Wilmington, MA, USA).
They were first deprotected with a solution of bromotrimethylsi-
lane/pyridine (3:2, v/v) in dichloromethane for the (E)-vinylphosph-
onate deprotection, then cleaved and deprotected with 40% aq.
methylamine at 45C for 1 h. Oligonucleotides were purified using
an Agilent Prostar System (Agilent, Santa Clara, CA, USA) over a
C18 column for lipid-conjugated sense strands and over an ion-ex-
change column for antisense strands. Purified oligonucleotides were
desalted by size-exclusion chromatography and characterized by
liquid chromatography-mass spectrometry (LC/MS) analysis on an
Agilent 6530 accurate-mass quadrupole time-of-flight (Q-TOF) LC/
MS (Agilent Technologies, Santa Clara, CA, USA).
Injection of lipid-conjugated siRNAs into mice
Animal experiments were performed in accordance with animal care
ethics approval and guidelines of University of Massachusetts Medi-
cal School Institutional Animal Care and Use Committee (IACUC;
protocol number A-2411). In all experiments, 7-week-old female
FVB/NJ mice were used and were injected s.c. with either phos-
phate-buffered saline (PBS controls), non-targeting control siRNA
(Ntc), or lipid-conjugated siRNA (n = 6 per group).
PNA hybridization assay
Quantification of antisense strands in tissues was performed using a
PNA hybridization assay as described.45,73 In brief, tissues (10 mg)
were lysed in 200 mL MasterPure tissue lysis solution (EpiCentre)
containing 0.2 mg/mL Proteinase K (Invitrogen). Sodium dodecyl
sulfate (SDS) was precipitated from lysates by adding 20 mL 3 M po-
tassium chloride and pelleted centrifugation at 5,000  g for 15 min.
Lipid-conjugated siRNAs in cleared supernatant were hybridized to a
Cy3-labeled PNA probe fully complementary to the antisense strand
(PNABio; Thousand Oaks, CA, USA). Samples were analyzed by
high-performance liquid chromatography (HPLC; Agilent, Santa
Clara, CA, USA) over a DNAPac PA100 anion-exchange column
(Thermo Fisher Scientific). Cy3 fluorescence was monitored and
peaks integrated. Final concentrations were ascertained using calibra-
tion curves.
In vivo mRNA silencing experiments
At 1 week post-injection or 1 month post-injection, tissues were
collected and stored in RNAlater (Sigma) at 4C overnight. mRNA
was quantified using the QuantiGene 2.0 Assay (Affymetrix). Tissue
punches were lysed in 300 mL Homogenizing Buffer (Affymetrix)
containing 0.2 mg/mL Proteinase K (Invitrogen). Diluted lysates
and probe sets (mouse Htt, mouseMstn, or mouse Hprt) were added
to the bDNA capture plate, and the signal was amplified and detected
as described by Coles et al.74 Luminescence was detected on a Tecan
M1000 (Tecan, Morrisville, NC, USA).
In vivo protein silencing experiments
Blood was collected by terminal cardiac puncture, and serum was
analyzed for MSTN protein using the GDF-8/Myostatin Quantikine
ELISA kit (R&D Systems, Minneapolis, MN, USA). Serum samples
were activated as described in the manufacturer’s protocol, with the
exception that the final activated serum sample had an additional
1:2 dilution in calibrator diluent before assaying.
Cytokine level measurement
Mice were injected s.c. with DCA- and Chol-conjugated siRNAs
at both 50 and 100 mg/kg. At 24 h post-injection, blood was collected
by terminal cardiac puncture, and serum was analyzed for cytokine
concentration measurement using Customized Luminex Assay
(R&D Systems, Minneapolis, MN, USA). Serum samples were
analyzed as described in the manufacturer’s protocol.
Statistical analysis
Data were analyzed using GraphPad Prism 7.01 software (GraphPad
Software, San Diego, CA, USA). For each independent experiment in
mice, the level of silencing was normalized to the mean of the PBS
control group. Data were analyzed using non-parametric one-way
ANOVA with Dunnett test for multiple comparisons, with signifi-
cance calculated relative to PBS controls and t test for comparison
of two groups.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.
1016/j.ymthe.2020.12.023.
ACKNOWLEDGMENTS
We thank all Khvorova lab members for insightful discussions and
support, and Emily Haberlin for helping with the manuscript writing
and editing. This work was supported by National Institutes of Health
grants R01 HD086111, S10 OD020012, and R35 GM131839.
AUTHOR CONTRIBUTIONS
A.B. and A.K. conceived the project, designed the study, and wrote the
manuscript. A.B. synthesized most of the compounds and performed
most of the experiments and data analysis. J.C. helped with mouse
Molecular Therapy
10 Molecular Therapy Vol. 29 No 4 April 2021
Please cite this article in press as: Biscans et al., Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles,
Molecular Therapy (2020), https://doi.org/10.1016/j.ymthe.2020.12.023
handling. N.M. contributed to compound synthesis. V.H. and M.M
helped with cytotoxicity studies.
DECLARATION OF INTERESTS
A.K. owns stock of RXi Pharmaceuticals and Advirna. The other au-
thors declare no competing interests.
REFERENCES
1. Zhou, J., Shum, K.-T., Burnett, J.C., and Rossi, J.J. (2013). Nanoparticle-based deliv-
ery of RNAi therapeutics: progress and challenges. Pharmaceuticals (Basel) 6, 85–107.
2. Nair, J.K., Willoughby, J.L.S., Chan, A., Charisse, K., Alam,M.R., Wang, Q., Hoekstra,
M., Kandasamy, P., Kel’in, A.V., Milstein, S., et al. (2014). Multivalent N-acetylgalac-
tosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-medi-
ated gene silencing. J. Am. Chem. Soc. 136, 16958–16961.
3. Zimmermann, T.S., Karsten, V., Chan, A., Chiesa, J., Boyce, M., Bettencourt, B.R.,
Hutabarat, R., Nochur, S., Vaishnaw, A., and Gollob, J. (2017). Clinical proof of
concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate. Mol. Ther. 25,
71–78.
4. Jackson, A.L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J.M.,
Lim, L., Karpilow, J., Nichols, K., et al. (2006). Position-specific chemical modification
of siRNAs reduces “off-target” transcript silencing. RNA 12, 1197–1205.
5. Akinc, A., Maier, M.A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S.,
Ansell, S., Du, X., Hope, M.J., Madden, T.D., et al. (2019). The Onpattro story and
the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat.
Nanotechnol. 14, 1084–1087.
6. Setten, R.L., Rossi, J.J., and Han, S.P. (2019). The current state and future directions of
RNAi-based therapeutics. Nat. Rev. Drug Discov. 18, 421–446.
7. Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B.R., Strahs, A., Clausen, V.,
Wijngaard, P., Horton, J.D., Taubel, J., Brooks, A., et al. (2017). A Highly Durable
RNAi Therapeutic Inhibitor of PCSK9. N. Engl. J. Med. 376, 41–51.
8. Ray, K.K., Wright, R.S., Kallend, D., Koenig, W., Leiter, L.A., Raal, F.J., Bisch, J.A.,
Richardson, T., Jaros, M., Wijngaard, P.L.J., and Kastelein, J.J.P.; ORION-10 and
ORION-11 Investigators (2020). Two Phase 3 Trials of Inclisiran in Patients with
Elevated LDL Cholesterol. N. Engl. J. Med. 382, 1507–1519.
9. Osborn, M.F., and Khvorova, A. (2018). Improving siRNA delivery In vivo through
Lipid conjugation. Nucleic Acid Ther. 28, 128–136.
10. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M.,
Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004). Therapeutic silencing
of an endogenous gene by systemic administration of modified siRNAs. Nature 432,
173–178.
11. Foster, D.J., Brown, C.R., Shaikh, S., Trapp, C., Schlegel, M.K., Qian, K., Sehgal, A.,
Rajeev, K.G., Jadhav, V., Manoharan, M., et al. (2018). Advanced siRNA designs
further improve in vivo performance of GalNAc-siRNA conjugates. Mol. Ther. 26,
708–717.
12. Allerson, C.R., Sioufi, N., Jarres, R., Prakash, T.P., Naik, N., Berdeja, A., Wanders, L.,
Griffey, R.H., Swayze, E.E., and Bhat, B. (2005). Fully 20-modified oligonucleotide
duplexes with improved in vitro potency and stability compared to unmodified small
interfering RNA. J. Med. Chem. 48, 901–904.
13. Nair, J.K., Attarwala, H., Sehgal, A., Wang, Q., Aluri, K., Zhang, X., Gao, M., Liu, J.,
Indrakanti, R., Schofield, S., et al. (2017). Impact of enhanced metabolic stability on
pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates. Nucleic
Acids Res. 45, 10969–10977.
14. Nallagatla, S.R., and Bevilacqua, P.C. (2008). Nucleoside modifications modulate acti-
vation of the protein kinase PKR in an RNA structure-specific manner. RNA 14,
1201–1213.
15. Geary, R.S., Norris, D., Yu, R., and Bennett, C.F. (2015). Pharmacokinetics, bio-
distribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev.
87, 46–51.
16. Eckstein, F. (2002). Developments in RNA chemistry, a personal view. Biochimie 84,
841–848.
17. Haraszti, R.A., Roux, L., Coles, A.H., Turanov, A.A., Alterman, J.F., Echeverria, D.,
Godinho, B.M.D.C., Aronin, N., and Khvorova, A. (2017). 50-Vinylphosphonate im-
proves tissue accumulation and efficacy of conjugated siRNAs in vivo. Nucleic Acids
Res. 45, 7581–7592.
18. Parmar, R., Willoughby, J.L.S., Liu, J., Foster, D.J., Brigham, B., Theile, C.S., Charisse,
K., Akinc, A., Guidry, E., Pei, Y., et al. (2016). 50-(E)-Vinylphosphonate: a stable phos-
phate mimic can improve the RNAi activity of siRNA–GalNAc conjugates.
ChemBioChem 17, 985–989.
19. Hassler, M.R., Turanov, A.A., Alterman, J.F., Haraszti, R.A., Coles, A.H., Osborn,
M.F., Echeverria, D., Nikan, M., Salomon, W.E., Roux, L., et al. (2018).
Comparison of partially and fully chemically-modified siRNA in conjugate-mediated
delivery in vivo. Nucleic Acids Res. 46, 2185–2196.
20. Huang, Y. (2017). Preclinical and clinical advances of GalNAc-decorated nucleic acid
therapeutics. Mol. Ther. Nucleic Acids 6, 116–132.
21. Rajeev, K.G., Nair, J.K., Jayaraman, M., Charisse, K., Taneja, N., O’Shea, J.,
Willoughby, J.L., Yucius, K., Nguyen, T., Shulga-Morskaya, S., et al. (2015).
Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent
N-acetylgalactosamine elicits robust gene silencing in vivo. ChemBioChem 16,
903–908.
22. Matsuda, S., Keiser, K., Nair, J.K., Charisse, K., Manoharan, R.M., Kretschmer, P.,
Peng, C.G., V Kel’in, A., Kandasamy, P., Willoughby, J.L., et al. (2015). siRNA con-
jugates carrying sequentially assembled trivalent N-acetylgalactosamine linked
through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem.
Biol. 10, 1181–1187.
23. Prakash, T.P., Graham, M.J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K.,
Zhao, C., Aghajan, M., Murray, H.F., et al. (2014). Targeted delivery of antisense ol-
igonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves
potency 10-fold in mice. Nucleic Acids Res. 42, 8796–8807.
24. Tanowitz, M., Hettrick, L., Revenko, A., Kinberger, G.A., Prakash, T.P., and Seth, P.P.
(2017). Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalac-
tosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides
into liver hepatocytes. Nucleic Acids Res. 45, 12388–12400.
25. Raal, F.J., Kallend, D., Ray, K.K., Turner, T., Koenig, W., Wright, R.S., Wijngaard,
P.L.J., Curcio, D., Jaros, M.J., Leiter, L.A., and Kastelein, J.J.P.; ORION-9
Investigators (2020). Inclisiran for the Treatment of Heterozygous Familial
Hypercholesterolemia. N. Engl. J. Med. 382, 1520–1530.
26. Aartsma-Rus, A., and Krieg, A.M. (2017). FDA Approves Eteplirsen for Duchenne
Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga. Nucleic Acid Ther.
27, 1–3.
27. Wood, M.J.A., Talbot, K., and Bowerman, M. (2017). Spinal muscular atrophy: anti-
sense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
Hum. Mol. Genet. 26 (R2), R151–R159.
28. Gebski, B.L., Mann, C.J., Fletcher, S., and Wilton, S.D. (2003). Morpholino antisense
oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum.
Mol. Genet. 12, 1801–1811.
29. Hagstrom, J.E., Hegge, J., Zhang, G., Noble, M., Budker, V., Lewis, D.L., Herweijer, H.,
and Wolff, J.A. (2004). A facile nonviral method for delivering genes and siRNAs to
skeletal muscle of mammalian limbs. Mol. Ther. 10, 386–398.
30. Kawakami, E., Kawai, N., Kinouchi, N., Mori, H., Ohsawa, Y., Ishimaru, N., Sunada,
Y., Noji, S., and Tanaka, E. (2013). Local applications of myostatin-siRNA with ate-
locollagen increase skeletal muscle mass and recovery of muscle function. PLoS ONE
8, e64719.
31. Dowdy, S.F. (2017). Overcoming cellular barriers for RNA therapeutics. Nat.
Biotechnol. 35, 222–229.
32. Biscans, A., Coles, A., Haraszti, R., Echeverria, D., Hassler, M., Osborn, M., and
Khvorova, A. (2019). Diverse lipid conjugates for functional extra-hepatic siRNA de-
livery in vivo. Nucleic Acids Res. 47, 1082–1096.
33. Biscans, A., Coles, A., Echeverria, D., and Khvorova, A. (2019). The valency of fatty
acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo.
J. Control. Release 302, 116–125.
34. Osborn, M.F., Coles, A.H., Biscans, A., Haraszti, R.A., Roux, L., Davis, S., Ly, S.,
Echeverria, D., Hassler, M.R., Godinho, B.M.D.C., et al. (2019). Hydrophobicity
www.moleculartherapy.org
Molecular Therapy Vol. 29 No 4 April 2021 11
Please cite this article in press as: Biscans et al., Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles,
Molecular Therapy (2020), https://doi.org/10.1016/j.ymthe.2020.12.023
drives the systemic distribution of lipid-conjugated siRNAs via lipid transport path-
ways. Nucleic Acids Res. 47, 1070–1081.
35. Yuan, H., Lanting, L., Xu, Z.-G., Li, S.-L., Swiderski, P., Putta, S., Jonnalagadda, M.,
Kato, M., and Natarajan, R. (2008). Effects of cholesterol-tagged small interfering
RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a
mouse model of type 1 diabetes. Am. J. Physiol. Renal Physiol. 295, F605–F617.
36. Turanov, A.A., Lo, A., Hassler, M.R., Makris, A., Ashar-Patel, A., Alterman, J.F.,
Coles, A.H., Haraszti, R.A., Roux, L., Godinho, B.M.D.C., et al. (2018). RNAi modu-
lation of placental sFLT1 for the treatment of preeclampsia. Nat. Biotechnol. 36,
1164–1173.
37. Prakash, T.P., Mullick, A.E., Lee, R.G., Yu, J., Yeh, S.T., Low, A., Chappell, A.E.,
Østergaard, M.E., Murray, S., Gaus, H.J., et al. (2019). Fatty acid conjugation
enhances potency of antisense oligonucleotides in muscle. Nucleic Acids Res. 47,
6029–6044.
38. Khan, T., Weber, H., DiMuzio, J., Matter, A., Dogdas, B., Shah, T., Thankappan, A.,
Disa, J., Jadhav, V., Lubbers, L., et al. (2016). Silencing myostatin using cholesterol-
conjugated siRNAs induces muscle growth. Mol. Ther. Nucleic Acids 5, e342.
39. Østergaard, M.E., Jackson, M., Low, A., E Chappell, A., G Lee, R., Peralta, R.Q., Yu, J.,
Kinberger, G.A., Dan, A., Carty, R., et al. (2019). Conjugation of hydrophobic moi-
eties enhances potency of antisense oligonucleotides in the muscle of rodents and
non-human primates. Nucleic Acids Res. 47, 6045–6058.
40. Van der Vusse, G.J., Glatz, J.F., Van Nieuwenhoven, F.A., Reneman, R.S., and
Bassingthwaighte, J.B. (1998). Transport of long-chain fatty acids across the muscular
endothelium. Adv. Exp. Med. Biol. 441, 181–191.
41. Chappell, A.E., Gaus, H.J., Berdeja, A., Gupta, R., Jo, M., Prakash, T.P., Oestergaard,
M., Swayze, E.E., and Seth, P.P. (2020). Mechanisms of palmitic acid-conjugated anti-
sense oligonucleotide distribution in mice. Nucleic Acids Res. 48, 4382–4395.
42. Biscans, A., Caiazzi, J., Davis, S., McHugh, N., Sousa, J., and Khvorova, A. (2020). The
chemical structure and phosphorothioate content of hydrophobically modified
siRNAs impact extrahepatic distribution and efficacy. Nucleic Acids Res. 48, 7665–
7680.
43. Eckstein, F. (2014). Phosphorothioates, essential components of therapeutic oligonu-
cleotides. Nucleic Acid Ther. 24, 374–387.
44. Gaus, H.J., Gupta, R., Chappell, A.E., Østergaard, M.E., Swayze, E.E., and Seth, P.P.
(2019). Characterization of the interactions of chemically-modified therapeutic nu-
cleic acids with plasma proteins using a fluorescence polarization assay. Nucleic
Acids Res. 47, 1110–1122.
45. Godinho, B.M.D.C., Gilbert, J.W., Haraszti, R.A., Coles, A.H., Biscans, A., Roux, L.,
Nikan, M., Echeverria, D., Hassler, M., and Khvorova, A. (2017). Pharmacokinetic
profiling of conjugated therapeutic oligonucleotides: a high-throughput method
based upon serial blood microsampling coupled to Peptide Nucleic Acid hybridiza-
tion assay. Nucleic Acid Ther. 27, 323–334.
46. Wolfrum, C., Shi, S., Jayaprakash, K.N., Jayaraman, M., Wang, G., Pandey, R.K.,
Rajeev, K.G., Nakayama, T., Charrise, K., Ndungo, E.M., et al. (2007). Mechanisms
and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25,
1149–1157.
47. Wickstrom, E. (1986). Oligodeoxynucleotide stability in subcellular extracts and cul-
ture media. J. Biochem. Biophys. Methods 13, 97–102.
48. Tsuchida, K. (2008). Targeting myostatin for therapies against muscle-wasting disor-
ders. Curr. Opin. Drug Discov. Devel. 11, 487–494.
49. Rodgers, B.D., Interlichia, J.P., Garikipati, D.K., Mamidi, R., Chandra, M., Nelson,
O.L., Murry, C.E., and Santana, L.F. (2009). Myostatin represses physiological hyper-
trophy of the heart and excitation-contraction coupling. J. Physiol. 587, 4873–4886.
50. Kinouchi, N., Ohsawa, Y., Ishimaru, N., Ohuchi, H., Sunada, Y., Hayashi, Y.,
Tanimoto, Y., Moriyama, K., and Noji, S. (2008). Atelocollagen-mediated local and
systemic applications of myostatin-targeting siRNA increase skeletal muscle mass.
Gene Ther. 15, 1126–1130.
51. Liu, C.-M., Yang, Z., Liu, C.-W., Wang, R., Tien, P., Dale, R., and Sun, L.Q. (2008).
Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia
mice. Gene Ther. 15, 155–160.
52. Alterman, J.F., Godinho, B.M.D.C., Hassler, M.R., Ferguson, C.M., Echeverria, D.,
Sapp, E., Haraszti, R.A., Coles, A.H., Conroy, F., Miller, R., et al. (2019). A divalent
siRNA chemical scaffold for potent and sustained modulation of gene expression
throughout the central nervous system. Nat. Biotechnol. 37, 884–894.
53. Reed, D.R., Bachmanov, A.A., and Tordoff, M.G. (2007). Forty mouse strain survey of
body composition. Physiol. Behav. 91, 593–600.
54. Wanke, R., Milz, S., Rieger, N., Ogiolda, L., Renner-Müller, I., Brem, G., Hermanns,
W., and Wolf, E. (1999). Overgrowth of skin in growth hormone transgenic mice
depends on the presence of male gonads. J. Invest. Dermatol. 113, 967–971.
55. Taniguchi, T., Miyauchi, E., Nakamura, S., Hirai, M., Suzue, K., Imai, T.,
Nomura, T., Handa, T., Okada, H., Shimokawa, C., et al. (2015). Plasmodium
berghei ANKA causes intestinal malaria associated with dysbiosis. Sci. Rep. 5,
15699.
56. Goemans, N.M., Tulinius, M., van den Hauwe, M., Kroksmark, A.-K., Buyse, G.,
Wilson, R.J., van Deutekom, J.C., de Kimpe, S.J., Lourbakos, A., and Campion, G.
(2016). Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in
Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study.
PLoS ONE 11, e0161955.
57. Shemesh, C.S., Yu, R.Z., Gaus, H.J., Greenlee, S., Post, N., Schmidt, K., Migawa, M.T.,
Seth, P.P., Zanardi, T.A., Prakash, T.P., et al. (2016). Elucidation of the
Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in
Rats and Monkeys. Mol. Ther. Nucleic Acids 5, e319.
58. Spitali, P., and Aartsma-Rus, A. (2012). Splice modulating therapies for human dis-
ease. Cell 148, 1085–1088.
59. Thornton, C.A., Wang, E., and Carrell, E.M. (2017). Myotonic dystrophy: approach
to therapy. Curr. Opin. Genet. Dev. 44, 135–140.
60. Tasfaout, H., Buono, S., Guo, S., Kretz, C., Messaddeq, N., Booten, S., Greenlee, S.,
Monia, B.P., Cowling, B.S., and Laporte, J. (2017). Antisense oligonucleotide-medi-
ated Dnm2 knockdown prevents and reverts myotubular myopathy in mice. Nat.
Commun. 8, 15661.
61. Lieberman, A.P., Yu, Z., Murray, S., Peralta, R., Low, A., Guo, S., Yu, X.X., Cortes, C.J.,
Bennett, C.F., Monia, B.P., et al. (2014). Peripheral androgen receptor gene suppres-
sion rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell
Rep. 7, 774–784.
62. Murray, S., Ittig, D., Koller, E., Berdeja, A., Chappell, A., Prakash, T.P., Norrbom, M.,
Swayze, E.E., Leumann, C.J., and Seth, P.P. (2012). TricycloDNA-modified oligo-20-
deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-he-
patic tissues–a comparative study of oligonucleotide length, design and chemistry.
Nucleic Acids Res. 40, 6135–6143.
63. Sarett, S.M., Werfel, T.A., Lee, L., Jackson, M.A., Kilchrist, K.V., Brantley-Sieders, D.,
and Duvall, C.L. (2017). Lipophilic siRNA targets albumin in situ and promotes
bioavailability, tumor penetration, and carrier-free gene silencing. Proc. Natl. Acad.
Sci. USA 114, E6490–E6497.
64. Wada, S., Yasuhara, H., Wada, F., Sawamura, M., Waki, R., Yamamoto, T., Harada-
Shiba, M., and Obika, S. (2016). Evaluation of the effects of chemically different
linkers on hepatic accumulations, cell tropism and gene silencing ability of choles-
terol-conjugated antisense oligonucleotides. J. Control. Release 226, 57–65.
65. Zlatev, I., Castoreno, A., Brown, C.R., Qin, J., Waldron, S., Schlegel, M.K., Degaonkar,
R., Shulga-Morskaya, S., Xu, H., Gupta, S., et al. (2018). Reversal of siRNA-mediated
gene silencing in vivo. Nat. Biotechnol. 36, 509–511.
66. Geary, R.S. (2009). Antisense oligonucleotide pharmacokinetics and metabolism.
Expert Opin. Drug Metab. Toxicol. 5, 381–391.
67. Oberbauer, R., Schreiner, G.F., and Meyer, T.W. (1995). Renal uptake of an 18-mer
phosphorothioate oligonucleotide. Kidney Int. 48, 1226–1232.
68. Brown, D.A., Kang, S.H., Gryaznov, S.M., DeDionisio, L., Heidenreich, O., Sullivan,
S., Xu, X., and Nerenberg, M.I. (1994). Effect of phosphorothioate modification of oli-
godeoxynucleotides on specific protein binding. J. Biol. Chem. 269, 26801–26805.
69. Ansseau, E., Vanderplanck, C., Wauters, A., Harper, S.Q., Coppée, F., and Belayew, A.
(2017). Antisense oligonucleotides used to target the DUX4 mRNA as therapeutic
approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD). Genes (Basel)
8, 93.
70. Corey, D.R. (2017). Nusinersen, an antisense oligonucleotide drug for spinal
muscular atrophy. Nat. Neurosci. 20, 497–499.
Molecular Therapy
12 Molecular Therapy Vol. 29 No 4 April 2021
Please cite this article in press as: Biscans et al., Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles,
Molecular Therapy (2020), https://doi.org/10.1016/j.ymthe.2020.12.023
71. Aartsma-Rus,A., andCorey,D.R. (2020). The10thOligonucleotideTherapyApproved:
Golodirsen for Duchenne Muscular Dystrophy. Nucleic Acid Ther. 30, 67–70.
72. Nikan, M., Osborn, M.F., Coles, A.H., Godinho, B.M., Hall, L.M., Haraszti, R.A.,
Hassler, M.R., Echeverria, D., Aronin, N., and Khvorova, A. (2016).
Docosahexaenoic acid conjugation enhances distribution and safety of siRNA
upon local administration in mouse brain. Mol. Ther. Nucleic Acids 5, e344.
73. Roehl, I., Schuster, M., and Seiffert, S. (2011). Oligonucleotide detection method. US
Patent US20110201006A1, filed October 6, 2009 and granted July 14, 2020.
74. Coles, A.H., Osborn, M.F., Alterman, J.F., Turanov, A.A., Godinho, B.M.,
Kennington, L., Chase, K., Aronin, N., and Khvorova, A. (2016). A high-throughput
method for direct detection of therapeutic oligonucleotide-induced gene silencing
in vivo. Nucleic Acid Ther. 26, 86–92.
www.moleculartherapy.org
Molecular Therapy Vol. 29 No 4 April 2021 13
Please cite this article in press as: Biscans et al., Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles,
Molecular Therapy (2020), https://doi.org/10.1016/j.ymthe.2020.12.023
